title: Trastuzumab in the management of early and advanced stage breast cancer.
abstract: Trastuzumab is a monoclonal humanized antibody that has revolutionized the treatment of patients with Her2-positive breast cancer. Already well established in advanced stage disease, the substance was recently introduced in the adjuvant setting, reducing disease recurrences by more than 50% and mortality by approximately one third. Trastuzumab is a rationally designed substance which binds to cancer cells expressing the targeted antigen, and, by different mechanisms, causes tumor cell degradation. However, only one third of patients have an initial response to trastuzumab therapy, and the majority of initial responders demonstrate disease progression within 1 year of treatment initiation. It is therefore necessary to gain further insight into mechanisms of resistance, and develop ways to overcome those. In this article, the role of trastuzumab in early and advanced stage breast cancer is reviewed. We discuss current understandings of the specific tumor biology of Her2-positive breast cancer, and review the mechanism of action of trastuzumab. Further, we try to highlight possible mechanisms of resistance.
authors.affiliation: First Department of Medicine and Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
authors.forename: Rupert
authors.initials: R
authors.lastname: Bartsch
authors.forename: Catharina
authors.initials: C
authors.lastname: Wenzel
authors.forename: Guenther G
authors.initials: GG
authors.lastname: Steger
references.citation: J Clin Oncol. 1996 Mar;14(3):737-44
references.pmid: 8622019
references.citation: Nature. 2003 Feb 13;421(6924):756-60
references.pmid: 12610629
references.citation: Mol Cancer Ther. 2002 Jul;1(9):707-17
references.pmid: 12479367
references.citation: Br J Cancer. 2004 Aug 16;91(4):639-43
references.pmid: 15266327
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2162-71
references.pmid: 15800309
references.citation: Cancer Res. 2001 Jun 15;61(12):4892-900
references.pmid: 11406568
references.citation: Ann Pathol. 2003 Dec;23(6):617-22
references.pmid: 15094603
references.citation: J Clin Oncol. 2004 Jan 15;22(2):322-9
references.pmid: 14722042
references.citation: J Clin Oncol. 2007 May 20;25(15):2012-8
references.pmid: 17513805
references.citation: J Clin Oncol. 2003 Jan 1;21(1):46-53
references.pmid: 12506169
references.citation: Nat Med. 2000 Apr;6(4):443-6
references.pmid: 10742152
references.citation: J Clin Pathol. 2000 Dec;53(12):890-2
references.pmid: 11265171
references.citation: Cancer Res. 2006 Feb 1;66(3):1630-9
references.pmid: 16452222
references.citation: J Mol Cell Cardiol. 2003 Dec;35(12):1473-9
references.pmid: 14654373
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Radiother Oncol. 2006 Sep;80(3):313-7
references.pmid: 16959347
references.citation: Ann Oncol. 2001;12 Suppl 1:S21-2
references.pmid: 11521716
references.citation: J Clin Oncol. 2004 Mar 15;22(6):1063-70
references.pmid: 15020607
references.citation: Clin Cancer Res. 2004 Jul 1;10(13):4457-63
references.pmid: 15240537
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3676-85
references.pmid: 15738535
references.citation: Oncogene. 1998 Oct 29;17(17):2235-49
references.pmid: 9811454
references.citation: Semin Oncol. 2002 Jun;29(3 Suppl 11):29-37
references.pmid: 12138395
references.citation: Biochim Biophys Acta. 1994 Dec 30;1198(2-3):165-84
references.pmid: 7819273
references.citation: Nat Clin Pract Oncol. 2006 May;3(5):269-80
references.pmid: 16683005
references.citation: J Cell Physiol. 2004 Sep;200(3):343-50
references.pmid: 15254961
references.citation: Nature. 2002 Jan 31;415(6871):530-6
references.pmid: 11823860
references.citation: Oncogene. 1994 Jul;9(7):1829-38
references.pmid: 7911565
references.citation: Biochem J. 1999 Dec 1;344 Pt 2:339-48
references.pmid: 10567214
references.citation: J Mol Diagn. 2004 Feb;6(1):42-51
references.pmid: 14736826
references.citation: Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S
references.pmid: 14734488
references.citation: Cancer Res. 2004 Jun 1;64(11):3981-6
references.pmid: 15173011
references.citation: Cancer Res. 2002 Jul 15;62(14):4132-41
references.pmid: 12124352
references.citation: Clin Breast Cancer. 2003 Jun;4(2):120-5
references.pmid: 12864940
references.citation: Cancer. 2002 Oct 1;95(7):1592-600
references.pmid: 12237930
references.citation: Clin Breast Cancer. 2004 Jun;5(2):142-7
references.pmid: 15245619
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3965-71
references.pmid: 14507946
references.citation: Int J Cancer. 1991 Nov 11;49(5):650-5
references.pmid: 1682277
references.citation: Int J Clin Oncol. 2006 Jun;11(3):199-208
references.pmid: 16850126
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2889-95
references.pmid: 12885806
references.citation: Cancer Res. 2001 Jun 15;61(12):4744-9
references.pmid: 11406546
references.citation: Eur J Cancer. 2007 Feb;43(3):497-509
references.pmid: 17223541
references.citation: Oncogene. 1999 Apr 1;18(13):2241-51
references.pmid: 10327070
references.citation: Mol Cell Biol. 2001 Jun;21(12):3995-4004
references.pmid: 11359907
references.citation: Science. 1989 May 12;244(4905):707-12
references.pmid: 2470152
references.citation: Cancer Res. 2006 Feb 1;66(3):1640-7
references.pmid: 16452223
references.citation: Oncologist. 2002;7(5):410-7
references.pmid: 12401903
references.citation: J Clin Oncol. 1998 Aug;16(8):2659-71
references.pmid: 9704716
references.citation: Mol Cell Biol. 1988 Mar;8(3):1019-26
references.pmid: 2897079
references.citation: Anticancer Res. 2002 Jul-Aug;22(4):2485-90
references.pmid: 12174949
references.citation: Cancer Res. 1999 Mar 15;59(6):1347-55
references.pmid: 10096569
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: J Clin Oncol. 2005 Jul 1;23(19):4265-74
references.pmid: 15911866
references.citation: Oncogene. 2000 Jul 20;19(31):3460-9
references.pmid: 10918604
references.citation: BMC Cancer. 2006 Mar 15;6:63
references.pmid: 16539726
references.citation: Eur J Cancer. 2004 Feb;40(3):379-82
references.pmid: 14746856
references.citation: N Engl J Med. 2006 Feb 23;354(8):809-20
references.pmid: 16495393
references.citation: Cancer. 1986 Aug 15;58(4):832-9
references.pmid: 3755076
references.citation: Cancer. 1992 Feb 15;69(4):972-80
references.pmid: 1735089
references.citation: Cancer Chemother Pharmacol. 2010 Jul;66(2):269-76
references.pmid: 19904537
references.citation: J Clin Oncol. 2006 Apr 20;24(12):1831-8
references.pmid: 16549824
references.citation: Nature. 1986 Jan 16-22;319(6050):226-30
references.pmid: 3945311
references.citation: Biochemistry. 2004 Dec 28;43(51):16243-53
references.pmid: 15610018
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: J Clin Oncol. 1990 Jan;8(1):103-12
references.pmid: 1967301
references.citation: Breast Cancer Res Treat. 2007 May;102(3):375-81
references.pmid: 17028979
references.citation: Ann Oncol. 2006 Apr;17(4):630-6
references.pmid: 16410363
references.citation: Oncologist. 2006;11 Suppl 1:34-41
references.pmid: 16971738
references.citation: Exp Hematol. 1999 Oct;27(10):1533-41
references.pmid: 10517495
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3853-8
references.pmid: 17679724
references.citation: Clin Cancer Res. 2004 Mar 1;10(5):1706-16
references.pmid: 15014023
references.citation: N Engl J Med. 2005 Oct 20;353(16):1659-72
references.pmid: 16236737
references.citation: Nature. 2002 Mar 21;416(6878):279-80
references.pmid: 11907566
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Cancer Cell. 2004 Aug;6(2):117-27
references.pmid: 15324695
references.citation: N Engl J Med. 2002 Dec 19;347(25):1999-2009
references.pmid: 12490681
references.citation: J Clin Oncol. 2006 Sep 1;24(25):4107-15
references.pmid: 16908934
references.citation: J Cancer Res Clin Oncol. 2004 Jul;130(7):400-4
references.pmid: 15168107
references.citation: Cancer. 2003 Jun 15;97(12):2972-7
references.pmid: 12784331
references.citation: Endocr Relat Cancer. 2002 Jun;9(2):75-85
references.pmid: 12121832
references.citation: Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):5-13
references.pmid: 16736978
references.citation: Biochem Pharmacol. 2001 Nov 15;62(10):1311-36
references.pmid: 11709192
references.citation: Oncologist. 2003;8(4):307-25
references.pmid: 12897328
references.citation: Clin Cancer Res. 2004 Sep 1;10(17):5650-5
references.pmid: 15355889
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1993-9
references.pmid: 18421051
references.citation: Cancer Chemother Pharmacol. 2002 Mar;49(3):211-6
references.pmid: 11935213
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7
references.pmid: 11752009
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2786-92
references.pmid: 16782917